医学
贝伐单抗
内科学
肿瘤科
肺癌
化学免疫疗法
不利影响
临床试验
人口
化疗
癌症
免疫疗法
环境卫生
作者
Jiarui Chen,Xingyu Liu,Mengjie Zhang,Zhao Huang,Wenbin Zeng,Jing Hu,Gang Chen,Yan Gong,Yu Liu,Cong Xie
出处
期刊:Future Oncology
[Future Medicine]
日期:2022-04-01
卷期号:18 (13): 1651-1664
被引量:3
标识
DOI:10.2217/fon-2021-0838
摘要
Aim: To review the efficacy and safety of regimens containing anti-PD-1/PD-L1 and bevacizumab for patients with advanced nonsquamous, non-small-cell lung cancer. Methods: Sixteen eligible trials were assessed. Clinical outcomes and adverse events were integrated. Subgroup analysis was conducted according to PD-L1 expression and liver metastases. Results: For the PD-L1 high population, a PD-1 inhibitor plus platinum-doublet provided significant progression-free survival (PFS) benefit versus bevacizumab. While for patients harboring PD-L1 <50%, anti-PD-1/PD-L1-containing regimens performed comparably to bevacizumab. With regard to the liver metastatic population, there existed a trend that anti-PD-1 plus chemotherapy brought about PFS benefits. Conclusion: The preference for chemoimmunotherapy lacks sufficient evidence in patients harboring PD-L1 <50%. Direct head-to-head clinical trials are warranted to identify optimal therapeutic regimens for specific patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI